Other antitrust authorities, such as the Federal Competition Authority of Austria and the National Authority for Markets and Competition in Spain, cleared the takeover in the past few weeks, according to the filing. BTG shareholders approved the purchase in March.
The fate of the deal is now in the hands of a British court, where a hearing is scheduled for Aug. 15, 2019. If the court agrees to the acquisition, it could close Aug. 19, 2019, with BTG shares canceled the next day.
The £8.40-per-share offer, worth about $4.24 billion (£3.3 billion), is slated to close in mid-2019. The purchase price is a 36.6% premium over BTG’s closing price the day before the Nov. 20 announcement and a 51.0% premium over the stock’s 90-day volume-weighted average price.
BTG’s largest division makes devices for oncology and vascular conditions; the company also makes overdose and antivenin drugs for snakebite.